Online citations, reference lists, and bibliographies.
← Back to Search

The 500 Dalton Rule For The Skin Penetration Of Chemical Compounds And Drugs

J. Bos, M. Meinardi
Published 2000 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract: Human skin has unique properties of which functioning as a physicochemical barrier is one of the most apparent. The human integument is able to resist the penetration of many molecules. However, especially smaller molecules can surpass transcutaneously. They are able to go by the corneal layer, which is thought to form the main deterrent. We argue that the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption. Larger molecules cannot pass the corneal layer. Arguments for this “500 Dalton rule” are; 1) virtually all common contact allergens are under 500 Dalton, larger molecules are not known as contact sensitizers. They cannot penetrate and thus cannot act as allergens in man; 2) the most commonly used pharmacological agents applied in topical dermatotherapy are all under 500 Dalton; 3) all known topical drugs used in transdermal drug‐delivery systems are under 500 Dalton. In addition, clinical experience with topical agents such as cyclosporine, tacrolimus and ascomycins gives further arguments for the reality of the 500 Dalton rule. For pharmaceutical development purposes, it seems logical to restrict the development of new innovative compounds to a MW of under 500 Dalton, when topical dermatological therapy or percutaneous systemic therapy or vaccination is the objective.
This paper references
A short-term trial of tacrolimus ointment for atopic dermatitis
TTILA (2000)
10.1001/ARCHDERM.1992.01680160070006
Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy.
M. K. Burns (1992)
A microplaque assay-based, double-blind trial to compare the efficacy of two tacrolimus ointment formulations with two active and two negative controls in patients with chronic plaque-type psoriasis
A Remitz (1996)
10.1001/archderm.1996.03890280081011
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group.
(1996)
10.1016/S0167-7799(97)01069-X
Transdermal therapy and diagnosis by iontophoresis.
Vila Merino (1997)
10.1007/978-3-0348-8464-8_1
Skin immune system (SIS)
J. Bos (2000)
10.1126/science.7638603
Ultrasound-mediated transdermal protein delivery
S. Mitragotri (1995)
10.1038/JIDSYMP.1998.27
The selection and design of topical and transdermal agents: a review.
J. Hadgraft (1998)
10.1038/JIDSYMP.1998.32
Skin electroporation causes molecular transport across the stratum corneum through localized transport regions.
T. Chen (1998)
Topical treatment with the macrolactam SDZ ASM 981 is effective in atopic dermatitis
J MVanLeentE (1998)
10.1016/0140-6736(91)91420-Y
Lack of effect of cyclosporin mouthwash in oral lichen planus
NicholasJ. Levell (1991)
10.1016/S0140-6736(88)91335-9
INTRALESIONAL INJECTION OF CYCLOSPORIN IN PSORIASIS
A. Powles (1988)
Drug delivery and targeting.
R. Langer (1998)
10.1073/PNAS.90.22.10504
Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery.
M. Prausnitz (1993)
Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis.
M. D. de Rie (1991)
Effect of topical cyclosporin rinse on oral lichen planus
D Eisen (1990)
10.1046/j.1365-2133.1998.02554.x
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
Mrowietz (1998)
10.1111/j.1365-2133.1990.tb08248.x
Topical cyclosporin A in psoriasis
H. Schulze (1990)
10.1111/1523-1747.EP12345542
Clearing of psoriasis by a novel immunosuppressive macrolide.
K. Rappersberger (1996)
10.1001/ARCHDERM.134.9.1101
Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.
I. Zonneveld (1998)
10.1016/S0140-6736(89)92941-3
USE OF CYCLOSPORIN IN PSORIASIS
J. Bos (1989)



This paper is referenced by
10.2147/CCID.S3378
Tacrolimus ointment in the management of atopic dermatitis
A. Baldo (2009)
10.1016/j.jconrel.2014.01.006
Topical delivery of siRNA into skin using SPACE-peptide carriers.
M. Chen (2014)
10.1016/j.neuroscience.2004.08.011
Integrin α2β1 affects mechano-transduction in slowly and rapidly adapting cutaneous mechanoreceptors in rat hairy skin
P. Khalsa (2004)
Pharmacokinetics of albuterol and butorphanol administered intravenously and via a buccal patch
D. F. Vaughan (2004)
10.1007/s11095-005-2591-x
Comparative Study of the Skin Penetration of Protein Transduction Domains and a Conjugated Peptide
Luciana B. Lopes (2005)
The Prevalence and Risk Factors of Contact Allergy in the Adult General Population
J. Thyssen (2009)
10.1016/j.clindermatol.2009.05.013
Cosmeceuticals and peptides.
L. Zhang (2009)
10.1517/17425240903304032
Cutaneous short-interfering RNA therapy
B. Geusens (2009)
10.1016/B978-0-08-087780-8.00101-7
F – Transdermal DDS
Gary W. Cleary (2013)
10.1021/mp3007083
Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery.
Priyanka E Ghosh (2013)
10.1007/978-1-4939-1289-6_11
Follicular Drug Penetration
Jürgen Lademann (2014)
Polymeric vehicles for topical delivery and related analytical methods
Heui Kyoung (2014)
NOVEL APPROACHES TO INCREASE TRANSDERMAL ABSORPTION
S. Raut (2014)
10.1007/s11095-015-1629-y
In Silico Predictions of Human Skin Permeability using Nonlinear Quantitative Structure–Property Relationship Models
Hiromi Baba (2015)
10.1007/s13671-014-0092-z
Perspectives on Using Nanoscale Delivery Systems in Dermatological Treatment
Marianna Foldvari (2015)
10.1016/j.pharma.2015.06.002
Perspectives and strategies of alternative methods used in the risk assessment of personal care products.
Paul Quantin (2015)
10.1371/journal.pone.0192113
Diastereoselective synthesis of chiral 1,3-cyclohexadienals
Aitor Urosa (2018)
10.1517/14712598.2014.853738
Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure
J. Chang (2014)
Safety of Nanotechnology in Sunscreens and Personal Care Products
Gerhard ()
10.1038/jid.2009.303
Dermal nitrite application enhances global nitric oxide availability: new therapeutic potential for immunomodulation?
María Francisca García-Saura (2010)
10.3390/pharmaceutics11080402
Micro-Pillar Integrated Dissolving Microneedles for Enhanced Transdermal Drug Delivery
Seunghee Lee (2019)
10.1016/j.biomaterials.2014.01.052
The transdermal inhibition of melanogenesis by a cell-membrane-permeable peptide delivery system based on poly-arginine.
N. Ookubo (2014)
10.1142/S1793545818500323
In vivo monitoring of microneedle-based transdermal drug delivery of insulin
Jiawei Zhao (2018)
10.1021/ACS.JNATPROD.6B00449
Rice Bran Protein as a Potent Source of Antimelanogenic Peptides with Tyrosinase Inhibitory Activity.
A. Ochiai (2016)
10.1007/978-1-62703-167-7_16
Nutrient-Rich Botanicals in Skin Health: Focus on Avena sativa
K. Mahmood (2013)
10.1517/17425247.2013.776038
Drug delivery to hair follicles
A. Patzelt (2013)
10.1080/13543784.2017.1353598
Experimental and early investigational drugs for androgenetic alopecia
H. Guo (2017)
10.1586/erv.13.48
Intradermal powder immunization with protein-containing vaccines
Nikolas T Weissmueller (2013)
10.1016/j.jep.2009.09.046
Transdermal behaviour of the N-alkylamide spilanthol (affinin) from Spilanthes acmella (Compositae) extracts.
J. Boonen (2010)
10.1002/jbm.a.35770
Development of a nanofibrous wound dressing with an antifibrogenic properties in vitro and in vivo model.
Malihe-Sadat Poormasjedi-Meibod (2016)
10.1080/15287390903212246
Safety Evaluation of Disposable Baby Diapers Using Principles of Quantitative Risk Assessment
Prashant Rai (2009)
10.1016/j.jconrel.2010.09.018
Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
S. Bal (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar